INT-210
/ Innatus Therapeutics
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
July 03, 2026
A Phase I Study of INT-210 Capsules in Healthy Adult Subjects (INT-210-I101)
(clinicaltrials.gov)
- P1 | N=86 | Completed | Sponsor: Innatus Therapeutics (Shanghai) Co., Ltd. | Recruiting ➔ Completed
Trial completion • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease
June 02, 2026
A Phase I Study of INT-210 Capsules in Healthy Adult Subjects (INT-210-I101)
(clinicaltrials.gov)
- P1 | N=86 | Completed | Sponsor: Innatus Therapeutics (Shanghai) Co., Ltd.
New P1 trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease
1 to 2
Of
2
Go to page
1